FTC pauses challenge to Amgen deal for Horizon Therapeutics, WSJ reports

The Federal Trade Commission suspended its challenge of Amgen’s (AMGN) $27.8B acquisition of Horizon Therapeutics (HZNP), giving the agency time to weigh a settlement that would allow the deal to close with conditions, The Wall Street Journal’s Dave Michaels reports. The FTC said in a court filing late Friday that it would pause a challenge it filed in its internal court that alleged the deal violates antitrust law. The pause, effective until Sept. 18, allows the FTC’s three commissioners to decide whether the agency should settle the case, the author adds.